Our team of myeloma experts develop and oversee clinical trials from inception to completion. Since our founding, over 350 patients have received myeloma treatment through one of our 9 multi-centre clinical trials. Our portfolio of clinical trials continues to grow each year.
Our Trials
CMRG 001
Status: Closed
A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression.
A number of strategies have been proposed to improve the outcome of ASCT. The three main strategies are to incorporate novel agents into the induction regimen, using maintenance therapy following ASCT and the final strategy is to enhance conditioning regimens. Investigators would like to explore all these three strategies in this study: Investigators propose to take patients who have had standard novel agent (bortezomib) based induction regimens into this study and then use a dose-adjusted combination of busulfan and melphalan as conditioning regimen and finally Investigators would like to incorporate lenalidomide maintenance post ASCT until disease progression.
Lead PI: Dr. Donna Reece
ClinicalTrials.gov Identifier NCT01702831
Participating Sites:
- Edmonton – Cross Cancer Institute
- Halifax – Queen Elizabeth II Health Sciences Centre
- London – London Health Science Centre
- Montreal – McGill University Health Centre
- Montreal – Hôpital Maisonneuve-Rosemont
- Ottawa – The Ottawa General Hospital
- Saint John – Saint John Regional Hospital
- Saskatoon – Saskatoon Cancer Centre
- Toronto – Princess Margaret Hospital
- Vancouver – Vancouver General Hospital
CMRG 002
Status: Closed
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
The Phase II trial combines selinexor, with dexamethasone and a “backbone” therapy: either bortezomib (Velcade®), lenalidomide (Revlimid®) or pomalidomide (Pomalyst®) in patients with relapsed or refractory myeloma. The therapies are given orally, with the exception of bortezomib, which is given by subcutaneous injection.
This trial is in collaboration with Karyopharm Therapeutics.
Lead PI: Dr. Nizar Bahlis and Dr. Christine Chen
ClinicalTrials.gov Identifier NCT02343042
Participating Sites:
- Calgary – Tom Baker Cancer Centre
- Edmonton – Cross Cancer Institute
- Halifax – Queen Elizabeth II Health Sciences Centre
- Montreal – Maisonneuve-Rosemont Hospital
- Montreal – Royal Victoria Hospital/McGill University
- Regina – Saskatchewan Cancer Agency – Allan Blair Cancer Centre
- St John’s – Memorial Hospital of Newfoundland
- Toronto – Princess Margaret Cancer Centre
- Vancouver – Vancouver General Hospital
- Winnipeg – CancerCare Manitoba
CMRG 003
Status: Closed
A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies
The currently approved dosing schedule for carfilzomib is twice weekly. This trial is evaluating a once-weekly dosing regimen that is more convenient for the patient and is also more cost-effective. The overall lower cost of this combination may help influence provincial drug funding decisions in the future.
Lead PI: Dr. Christopher Venner
ClinicalTrials.gov Identifier NCT02597062
Participating Sites:
- A special mention goes to the Cross Cancer Institute, Hôpital Maisonneuve-Rosemont and the Ottawa Hospital Research Institute who collectively accounted for more than half of total patient accrual.
- Edmonton – Cross Cancer Institute
- Halifax – Queen Elizabeth II Health Sciences Centre
- Kingston – Kingston General Hospital
- London – London Health Sciences Centre
- Montreal – Hôpital Maisonneuve-Rosemont
- Ottawa – The Ottawa General Hospital
- Quebec City – Pavillon Hôtel-Dieu de Québec
- Saint John – Saint John Regional Hospital
- Toronto – Princess Margaret Cancer Centre
CMRG 004
Status: Closed
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
This open-label trial is planned to recruit a total of 120 patients across Canada into two study arms. One group will receive daratumumab, cyclophosphamide, dexamethasone and pomalidomide (Pomalyst®). The other group will receive the same treatment regimen, however pomalidomide will only be added when the participant’s disease progresses.
Lead PI: Dr. Michael Sebag
ClinicalTrials.gov Identifier NCT03215524
Participating Sites:
- Calgary – Tom Baker Cancer Centre
- Edmonton – Cross Cancer Institute
- Halifax – Queen Elizabeth II Health Sciences Centre
- Hamilton – Juravinski Cancer Centre
- Ottawa – Ottawa General Hospital
- Saint John – Saint John Regional Hospital
- Saskatoon – Saskatoon Cancer Centre
- Surrey – BCCA Fraser Valley Centre
- Thunder Bay – Thunder Bay Regional HSC
- Toronto – Princess Margret Cancer Centre
- Winnipeg – CancerCare Manitoba
CMRG 005
Status: Open, actively recruiting
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
The study will compare the combination of selinexor, bortezomib (Velcade®) and dexamethasone (SVd) versus the combination bortezomib and dexamethasone (Vd) in patients with relapsed or refractory myeloma who have had 1-3 prior lines of therapy.
Lead PI: Dr. Nizar Bahlis
ClinicalTrials.gov Identifier NCT03110562
Participating Sites:
- Calgary – Tom Baker Cancer Centre
- Edmonton – Cross Cancer Institute
- Halifax – Queen Elizabeth II Health Sciences Centre
- Montreal – Hôpital Maisonneuve-Rosemont
- Montreal – Royal Victoria Hospital/McGill University
- Quebec City – Pavillon Hôtel-Dieu de Québec
- Toronto – Princess Margaret Cancer Centre
- Saskatoon – Saskatoon Cancer Centre
- Vancouver – Vancouver General Hospital
- Sudbury – Northeast Cancer Centre, Health Sciences North
CMRG 006
Status: Closed
A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added to The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib And Dexamethasone (CyBorD) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation
This is a phase 2A, pilot study of Pembrolizumab administered in combination with CyBorD in newly diagnosed, transplant ineligible multiple myeloma patients who achieve less than VGPR (according to IMWG criteria) after two cycles of treatment.
Lead PI: Dr. Rami Kotb
ClinicalTrials.gov Identifier NCT04258683
Participating Sites:
- Winnipeg – CancerCare Manitoba
- Moncton – The Moncton Hospital
- Sherbrooke – CIUSSS de L’Estrie-CHUS
- Regina – Allan Blair Cancer Centre
CMRG 007
Status: Open, actively recruiting
A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination with PO Pomalidomide and Low-Dose Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
Lead PI: Dr. Suzanne Trudel
ClinicalTrials.gov Identifier NCT03715478
This trial is a phase 1 and 2, single-arm, open-label, dose-escalation study that will evaluate the safety and efficacy of GSK2857916 in combination with pomalidomide and low-dose dexamethasone in subjects with relapsed and/or refractory multiple myeloma. Phase 1 will determine the recommended dosage, while Phase 2 will determine the efficacy of GSK2857916
Participating Sites:
- Halifax – Queen Elizabeth II Health Sciences Centre
- Ottawa – Ottawa General Hospital
- Hamilton – Juravinski Cancer Centre
- London – London Health Sciences Centre
- Toronto – Princess Margaret Cancer Centre
- Winnipeg – CancerCare Manitoba
- Regina – Allan Blair Cancer Centre
- Edmonton – Cross Cancer Institute
- Vancouver – Vancouver General Hospital
CMRG 008
Status: Open, closed for enrollment
A phase II study of Isatuximab added to standard CyBorD induction and Lenalidomide maintenance treatments in newly diagnosed, transplant eligible multiple myeloma
This is a phase II, multicenter, open label, single arm study that will evaluate the safety and efficacy of Isatuximab administered intravenously at 10 mg/kg in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a 28-day long cycle in autologous stem cell transplant-eligible patients.
Lead PI: Dr. Rami Kotb
ClinicalTrials.gov Identifier: NCT04786028
Participating sites:
- Edmonton- Cross Cancer Institute
- Winnipeg- CancerCare Manitoba
- Saint John- Eastern Health Sciences Centre
- Halifax- QEII Health Sciences Centre
- Hamilton- Juravinski Cancer Centre
- Ottawa- The Ottawa Hospital General Campus
- Sudbury- Health Sciences North
- Toronto- Princess Margaret Cancer Centre
- Regina- Alan Blair Cancer Centre
- Saskatoon- Saskatoon Cancer Centre
CMRG 009
Status: Closed
A Phase 2 Open Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Lead PI: Dr. Julie Stakiw
ClinicalTrials.gov Identifier NCT03697629
In this Phase II trial, patients with relapsed and/or refractory multiple myeloma will receive an accelerated infusion of daratumumab over a six-month time frame. Patients will be monitored to determine the incidence of infusion related reactions during the initial six months of daratumumab administration.
Participating Sites:
- Montreal – Hôpital Maisonneuve-Rosemont
- Montreal – Royal Victoria Hospital/ McGill University
- Kingston – Kingston General Hospital
- Toronto – Princess Margaret Cancer Centre
- Saskatoon – Saskatoon Cancer Agency
- Quebec City – Hopital de L’Enfant Jesus
